Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.58 |
| ▸ | CTSK | P43235 | 10/20 | 0.58 |
| ▸ | CTSB | P07858 | 4/20 | 0.58 |
| ▸ | CTSL | P07711 | 2/20 | 0.58 |
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18495337 | 1.00 | CTSS (0.58) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18495336 | 0.92 | CTSS (0.56) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18429598 | 0.92 | CTSS (0.56) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL21320234 | 0.91 | CTSS (0.55) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18495335 | 0.90 | CTSS (0.62) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL18429365 | 0.90 | CTSS (0.62) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10456411 | 0.90 | CTSS (0.69) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL10944784 | 0.90 | CTSS (0.69) | CTSSCTSKCTSBCTSLAKT1 | |
| SCHEMBL9011201 | 0.86 | PSMB1 (0.59) | CTSSCTSKCTSBCTSLREN | |
| SCHEMBL30100564 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-11-30 | — | — | US | disclosed |
| EP-3130608-B1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-3130608-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | Daiichi Sankyo Co., Ltd. (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170035906-A1 | (ANTI-HER2 ANTIBODY)-DRUG CONJUGATE | ERBB2, EGFR, LANCL2 | CTSS 1855/4885CTSK 2204/4885CTSB 625/4885 |
| US-11185594-B2 | (Anti-HER2 antibody)-drug conjugate | ERBB2, EGFR, LANCL2 | CTSS 1855/4885CTSK 2204/4885CTSB 625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.